SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies These are the first global Phase 3 ...
An update from Scancell Holdings ( ($GB:SCLP) ) is now available. Scancell Holdings has announced positive updated data from its SCOPE Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback